Vertex Pharmaceuticals (VRTX) FCF Margin (2009 - 2026)

Vertex Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 43.35% for Q1 2026.

• In Q1 2026, FCF Margin rose 1525.0% year-over-year to 43.35%; the TTM figure through Mar 2026 stood at 30.37% (up 4163.0% YoY), while the FY2025 annual figure was 26.61%, up 3378.0% from the prior year.
• FCF Margin for Q1 2026 stood at 43.35%, up from 10.93% in the prior quarter.
• The five-year high for FCF Margin was 49.47% in Q2 2022, with the low at 144.49% in Q2 2024.
• The 5-year median for FCF Margin is 38.61% (2022), against an average of 25.16%.
• The sharpest annual moves came in 2024 and 2025: FCF Margin plunged 18760 bps in 2024, then jumped 17577 bps in 2025.
• Vertex Pharmaceuticals' FCF Margin stood at 45.37% in 2022, then plunged by 85 bps to 7.01% in 2023, then soared by 141 bps to 16.9% in 2024, then tumbled by 35 bps to 10.93% in 2025, then jumped by 297 bps to 43.35% in 2026.
• Business Quant data shows VRTX's FCF Margin at 43.35% in Q1 2026, 10.93% in Q4 2025, and 37.04% in Q3 2025.